Great post @JSBStrikesBack. As a side not I would be interested to know peoples thoughts on whether they think the outstanding CMC issues for Rem-L outlined above by the poster is the main reason why the next COVID - ARDS trial has not progressed in any meaningful way that I am aware of with their collaboration partner the NIH (who will also fund it)? I think the NIH will not move forward with the next COVID - ARDS trial until these potency and quality attributes for Rem-L are given a formal tick of approval from OTAT? Would assume things would move forward quickly with the next trial assuming it is still a key focus for Mesoblast.
BLA resubmission for children with SR-aGVHD, page-2
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |